SYNGENE History

The Company was incorporated as Syngene International Private Limited on November 18, 1993 at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. Pursuant to a special resolution of the shareholders dated March 26, 2007, the Company was converted into a public limited company and the name of the Company was changed to Syngene International Limited. A fresh certificate of incorporation consequent upon conversion to public limited company was issued on April 19, 2007.
the Company was promoted by Kiran Mazumdar Shaw, a promoter of Biocon. On March 30, 2002, 99.9 percent of the Equity Shares of the Company were transferred to Biocon and as a result, the Company became the subsidiary of Biocon. Biocon has since been the Promoter of the Company.The details of changes in the registered office of the Company are given below: From 20th KM, Hosur Road, Electronics City P.O, Bengaluru 560 100, Karnataka, India to Biocon Special Economic Zone, Biocon Park, Plot No. 2 and 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bengaluru 560 099,
Karnataka, India.

Major events and milestones of the Company :


1994

-Initiated operations as a CRO with services in chemistry and biology

1998

-Granted 100% Export Oriented Unit (EOU) status by the Government of India

1999

-First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.

2000

-CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies

2001

-Forayed into chemical development with a dedicated manufacturing facility

2003

-Moved to Biocon Park, a 90 acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.

2007

-Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D centre

-Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.

-Crossed an annual turnover of over `1,000 million in Financial Year 2007


2009

-Dupont Crop Protection and the Company extended a partnership for R&D services

-Expansion of manufacturing services with a new plant which is cGMP compliant

-Initiated operations in safety assessment and large molecules development services

2010

-Acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, FDA

-Initiated operations in formulation development

2011

-Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer

2012

-Abbott and the Company collaborated to establish Abbott''s nutrition research and development centre in India and the second R&D centre

-Certification of the clinical facilities by ANVISA

-Acquired 100% stake in Clinigene International Limited from Biocon

2013

-Crossed an annual turnover of over `5,000 million in Financial Year 2013

-Baxter International Inc. collaborated with the Company to establish the ?Baxter Global Research Center?, the third dedicated R&D centre

-Acceptance of the control testing laboratory by the Department of Health & Human Services, FDA

2014

-Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D centre till 2020

-Acceptance of the API manufacturing facility by the Department of Health & Human Services, FDA

-Established a 75,000 sq.ft centre to provide stability and analytical services

2015
-CIL was amalgamated with the Company
Awards, Recognitions and Accreditations :

2009
- Bangalore Bio, Bio Excellence Award ? Biotech Services Sector
- Best BioServices company of the year by Biospectrum

2012
- ISO 9001:2008 for contract research in drug discovery and contract manufacturing of biopharmaceuticals
- AAALAC accreditation for conforming to the ?Guide for the Care and Use of Laboratory Animals and the Committee for the Purpose of Control and Supervision of Experiments on Animals guidelines?

2013
- Bioservices - ABLE Tenth Anniversary Award ? Outstanding contribution to Bioservices
- Diamond sponsor recognition by the Association of Scientists of Indian Origin of the Society of Toxicology

2014
- ISO 14001:2004 for contract research in drug discovery and contract manufacturing of biopharmaceuticals
- BS OHSAS 18001:2007 for contract research in drug discovery and contract manufacturing of biopharmaceuticals
- Silver EDGE Award
- EHS best practices award by CII
- SAP Ace Award for special recognition for complex SAP implementation
- Level I Laboratory certification issued by the NGSP to Clinigene International Limited

2015
- Accreditation by the College of American Pathologists in relation to their laboratory accreditation program
- Bangalore India Bio - Bio Excellence Award for outstanding contribution to the Biotech services sector
- ISO 15189:2007 in the field of medical testing

CIN: U67190WB2003PTC096617. Trading in Commodities is done through our Group Company Dynamic Commodities Pvt. Ltd. The company is also engaged in Proprietory Trading apart from Client Business.
“2019 © COPYRIGHT DYNAMIC EQUITIES PVT. LTD.”

Disclaimer: There is no guarantee of profits or no exceptions from losses. The investment advice provided are solely the personal views of the research team. You are advised to rely on your own judgment while making investment / Trading decisions. Past performance is not an indicator of future returns. Investment is subject to market risks. You should read and understand the Risk Disclosure Documents before trading/Investing.

Disclosure: We, Dynamic Equities Private Limited are also engaged in Proprietory Trading apart from Client Business. In case of any complaints/grievances, clients may write to us at compliance@dynamiclevels.com

  • Download our Mobile App
  • Available on Google Play
  • Available on App Store
  • RSS